These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34652477)

  • 1. [Rational follow-up of non-muscle invasive bladder cancer].
    von Landenberg N; Benderska-Söder N; Bismarck E; Kernig K; Erne E; Goebell PJ; Schmitz-Dräger BJ
    Urologe A; 2021 Nov; 60(11):1409-1415. PubMed ID: 34652477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
    Karaoglu I; van der Heijden AG; Witjes JA
    World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
    Benderska-Söder N; Hovanec J; Pesch B; Goebell PJ; Roghmann F; Noldus J; Rabinovich J; Wichert K; Gleichenhagen J; Käfferlein HU; Köhler CU; Johnen G; Kernig K; Hakenberg O; Jahn D; Todenhöfer T; Stenzl A; Gleissner J; Gerwert K; El-Mashtoly S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2020 Dec; 38(12):886-895. PubMed ID: 32199755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up in non-muscle invasive bladder cancer: facts and future.
    Witjes JA
    World J Urol; 2021 Nov; 39(11):4047-4053. PubMed ID: 33367941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
    Soukup V; Babjuk M; Bellmunt J; Dalbagni G; Giannarini G; Hakenberg OW; Herr H; Lechevallier E; Ribal MJ
    Eur Urol; 2012 Aug; 62(2):290-302. PubMed ID: 22609313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in the follow-up of nonmuscle invasive bladder cancer: what did we learn in the last 24 months: a critical review.
    Witjes JA
    Curr Opin Urol; 2020 May; 30(3):387-391. PubMed ID: 32141938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety.
    Dreyer T; Ernst A; Jensen JB
    Scand J Urol; 2022 Feb; 56(1):39-46. PubMed ID: 34913840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
    Zuiverloon TCM; de Jong FC; Theodorescu D
    Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
    PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aftercare of non-muscle invasive bladder cancer].
    Schulz GB; Schlenker B; Stief CG
    Urologe A; 2019 Aug; 58(8):943-952. PubMed ID: 31175377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatives to cytology in the management of non-muscle invasive bladder cancer.
    Amiel GE; Shu T; Lerner SP
    Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
    Schroeck FR; Lynch KE; Li Z; MacKenzie TA; Han DS; Seigne JD; Robertson DJ; Sirovich B; Goodney PP
    Cancer; 2019 Sep; 125(18):3147-3154. PubMed ID: 31120559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
    Hekman MCH; Wijn SRW; Lotan Y; Govers TM; Witjes JA
    World J Urol; 2023 Feb; 41(2):471-476. PubMed ID: 36534153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.